Vulvovaginitis Caused by Candida Species Following Antibiotic Exposure

  • Asmita Shukla
  • J. D. SobelEmail author
Female Genital Tract Infections (J Sobel, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Female Genital Tract Infections


Purpose of Review

Goal was to review epidemiology, pathophysiology, and prevention of post-antibiotic Candida vulvovaginitis (VVC).

Recent Findings

Antibacterial therapy, whether systemic or locally applied to the vagina, represents the single most frequent and predictable cause or triggering mechanism of symptomatic vulvovaginal candidiasis (VVC). Such initiating mechanisms may precipitate sporadic or recurrent episodes of VVC. In spite of this widely recognized association, the exact mechanism whereby antibiotics of all classes cause acute exacerbation of symptomatic vaginal disease remains largely unstudied and therefore largely unknown. Pathophysiology is hypothesized to be reduction or alteration of vaginal microbiome restraints of yeast colonization, proliferation, and expression of virulence characteristics.


The predictable link between antibiotic use and post-antibiotic VVC affords practitioners an opportunity for timely intervention using selective, convenient antimycotics usually drugs but possibly probiotic measures. Indications and limitation of these steps are discussed.


Vulvovaginitis Antibiotics Candidiasis Candida species 


Compliance with Ethical Standards

Conflict of Interest

All authors declare no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


  1. 1.
    Sobel JD. Recurrent vulvovaginal candidiasis. Am J Obstet Gynecol. 2016;214:15–21.CrossRefGoogle Scholar
  2. 2.
    Denning DW, Kneale M, Sobel JD, Rautemaa-Richardson R. Global burden of recurrent vulvovaginal candidiasis. A. Systematic review. Lancet Infect Dis. 2018;18:339–47.CrossRefGoogle Scholar
  3. 3.
    Marchaim D, Lemanek L, Bheemreddy S, Kaye KS, Sobel JD. Fluconazole-resistant, Candida albicans vulvovaginitis. Obstet Gynecol. 2012;120(6):1407–14.CrossRefGoogle Scholar
  4. 4.
    lj C. Vaginal moniliasis after tetracycline therapy: the effects of amphotericin B. Am J Obstet Gynecol. 1964;90:374–8.Google Scholar
  5. 5.
    Oriel JD, Waterworth PM. Effects of minocycline and tetracycline on the vaginal yeast flora. J Clin Pathol. 1975;28:403–6.CrossRefGoogle Scholar
  6. 6.
    Iravani A, Richard GA. Amoxicillin-clavulanic acid versus Cefaclor in the treatment of urinary tract infections and their effects on the urogenital and rectal flora. Antimicrob Ag Chemo. 1986;29:107–9.CrossRefGoogle Scholar
  7. 7.
    Bluestein D, Rutledge C, Lumsden L. Predicting the occurrence of antibiotic-induced candidal vaginitis (AICV). Fam Pract Res J. 1991;11:319–26.PubMedGoogle Scholar
  8. 8.
    MacDonald TM, Beardon PH, McGilchrist MM, Duncan ID, McKendrick AD, McDevitt DG. The risks of symptomatic vaginal candidiasis after oral antibiotic therapy. Q J Med. 1993;86:419–24.PubMedGoogle Scholar
  9. 9.
    Geiger AM, Foxman B. Risk factors for vulvovaginal candidiasis: a case-control study among university students. Epidemiology. 1996;7:182–7.CrossRefGoogle Scholar
  10. 10.
    Glover DD, Larsen B. Relationship of fungal vaginitis therapy to prior antibiotic exposure. Infect Dis Obstet Gyn. 2003;11:157–60.CrossRefGoogle Scholar
  11. 11.
    Spinillo A, Capuzzo E, Acciano A, Santolo AD, Zara F. Effect of antibiotic use on the prevalence of symptomatic vulvovaginal candidiasis. Am J Obstet Gynecol. 1999;180:14–7.CrossRefGoogle Scholar
  12. 12.
    Menday AP. Symptomatic vaginal candidiasis after pivmecillinam and norfloxacin treatment of acute uncomplicated lower urinary tract infection. Interna J Antimicrob Ag. 2002;20:297–300.CrossRefGoogle Scholar
  13. 13.
    Pirotta MV, Gunn JM, Chondros P. “Not thrush again!” Women’s experience of post-antibiotic vulvovaginitis. General Practice In Action. 2003;179:43–6.Google Scholar
  14. 14.
    Pirotta M, Gunn J, Chondros P, Grover S, O’Malley P, Hurley S, et al. Effect of lactobacillus in preventing post-antibiotic vulvovaginal candidiasis: a randomized controlled trial. BMJ. 2004;27:1–5.CrossRefGoogle Scholar
  15. 15.
    Pirotta MV, Garland SM. Genital Candida species detected in samples from women in Melbourne, Australia, before and after treatment with antibiotics. J Clin Micro. 2006;44:3213–7.CrossRefGoogle Scholar
  16. 16.
    Tabrizi SN, Pirotta MV, Rudland E, Garland SM. Detection of Candida species by PCR in self-collected vaginal swabs of women after taking antibiotics. Mycoses. 2006;49:523–4.CrossRefGoogle Scholar
  17. 17.
    Xu J, Schwartz K, Bartoces M, Monsur J, Severson RK, Sobel JD. Effect of antibiotics on vulvovaginal candidiasis: a MetroNet study. J Am Board Fam Med. 2008;21:261–8.CrossRefGoogle Scholar
  18. 18.
    Woods JW, Manning IH Jr, Patterson CN. Monilial infections complicating the therapeutic use of antibiotics. J Am Med Assoc. 1951;145(4):207–11.CrossRefGoogle Scholar
  19. 19.
    Miller CP. New problems in the treatment of infectious diseases. Ann Intern Med. 1951;35(4):763–70.CrossRefGoogle Scholar
  20. 20.
    Waterworth PM. The effect of minocycline on Candida albicans. J Clin Pathol. 1974;27:269–72.CrossRefGoogle Scholar
  21. 21.
    Glover DD, Larsen B. Longitudinal investigation of Candida vaginitis in pregnancy: role of superimposed antibiotic use. Obstet Gynecol. 1998;91:115–8.CrossRefGoogle Scholar
  22. 22.
    McVay LV Jr, Srunt DH. A study of moniliasis in aureomycin therapy. Proc Soc Exp Biol Med. 1951;78(3):759–61.CrossRefGoogle Scholar
  23. 23.
    Moore M. In vivo and in vitro effect of aureomycin hydrochloride on Syringospora (Monilia, Candida) albicans. J Lab Clin Med. 1951;37(5):703–12.PubMedGoogle Scholar
  24. 24.
    Huppert M, MacPherson DA, Cazin J. Pathogenesis of Candida Albicans infection following antibiotic therapy. Department of Bacteriology and Immunology, University of North Carolina School of Medicine. 1952;65:171–6.Google Scholar
  25. 25.
    Drell T, Lillsaar T, Tummeleht L, Simm J, Aaspõllu A, Väin E, et al. Characterization of the vaginal micro- and mycobiome in asymptomatic reproductive-age Estonian women. PLoS One. 2013;8(1):e54379. Scholar
  26. 26.
    Greenbaum S, Greenbaum G, Moran-Gilad J, Weintraub A. Ecological dynamics of the vaginal microbiome in relation to health and disease. Am J Obstet Gyn. 2019;220:324–36.CrossRefGoogle Scholar
  27. 26.
    Agnew KJ, Hillier SL. The effect of treatment regimens for vaginitis and cervicitis on vaginal colonization by lactobacilli. Sex Transm Dis. 1995 Sep-Oct;22(5):269–73.CrossRefGoogle Scholar
  28. 27.
    Sobel JD, Chaim W. Vaginal microbiology of women with acute recurrent vulvovaginal candidiasis. J Clin Microbiol. 1996;34(10):2497–9.PubMedPubMedCentralGoogle Scholar
  29. 28.
    St H, Hillier SL, Benedetti J, et al. Hydrogen peroxide-producing lactobacilli and acquisition of vaginal infection. J Infect Dis. 1996;174:1058–63.CrossRefGoogle Scholar
  30. 29.
    Chetwin E, Manhanzva MT, Abrahams AG, Froissart R, Gamieldien H, Jaspan H, et al. Antimicrobial and inflammatory properties of South African clinical Lactobacillus isolates and vaginal probiotics. Sci Rep. 2019;9:1917.CrossRefGoogle Scholar
  31. 30.
    Nichols RG, Peters JM, Patterson AD. Interplay between the host, the human microbiome, and drug metabolism. Hum Genomics. 2019;13(1):27.CrossRefGoogle Scholar
  32. 31.
    Swidsinski A, Guschin A, Tang Q, Dörffel Y, Verstraelen H, Tertychnyy A, et al. Vulvovaginal candidiasis: histologic lesions are primarily polymicrobial and invasive and do not contain biofilms. Am J Obstet Gynecol. 2019 Jan;220(1):91.e1–8.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Internal MedicineWayne State University School of MedicineDetroitUSA

Personalised recommendations